---
figid: PMC4676894__12943_2015_474_Fig2_HTML
figlink: /pmc/articles/PMC4676894/figure/Fig2/
number: Fig. 2
caption: 'Oncogenic (deregulated) intracellular signaling pathways in germinal center
  B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL). Germinal center B cell-like
  diffuse large B-cell lymphoma (GCB-DLBCL) are characterized by the inactivation
  or loss of the phosphatase and tensin homologue (PTEN) and S1PR2-Gα13-ARHGEF1 signaling
  pathways, which both negatively modulate GC B cell migration and phosphatidylinositol-3-kinase
  (PI3K) signaling [, –, , ]. In addition, activating mutations of the histone methyltransferase
  EZH2 (enhancer of zeste homologue 2) and master regulator of the GCB phenotype promote
  epigenetic changes that, at least partly, cooperate with the B-cell lymphoma 2 (BCL2)
  and BCL6 to mediate lymphomagenesis in GCB-DLBCL [, ]. A subset of GCB-DLBCL is
  characterized by translocations affecting the c-MYC and/or the BCL2 loci [, , ].
  These translocations lead to constitutive activation of c-MYC and the anti-apoptotic
  BCL2 protein and to a malignant transformation by preventing terminal differentiation
  or blocking apoptosis. The different colors that are used in the figure indicate
  molecules that belong to a specific pathway and/or lead to a specific outcome. Adapted
  from REF: [, , , ]. Information for this figure was gleaned from the following references:
  [, , , –, , , , , –, , , , , , , –, , , , , –, –, , , , , –, –, , ]. Abbreviations:
  S1PR2 sphingosine-1-phosphate receptor-2, Gα13 (GNA13) heterotrimeric G protein
  alpha 13, ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1, PI3K phosphoinositide
  3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, BCL6 B cell lymphoma
  protein 6, BCL2 B cell lymphoma protein 2, EZH2 enhancer of zeste homologue 2'
pmcid: PMC4676894
papertitle: 'Novel drug targets for personalized precision medicine in relapsed/refractory
  diffuse large B-cell lymphoma: a comprehensive review.'
reftext: Rosalba Camicia, et al. Mol Cancer. 2015;14:207.
pmc_ranked_result_index: '192089'
pathway_score: 0.9705936
filename: 12943_2015_474_Fig2_HTML.jpg
figtitle: Oncogenic (deregulated) intracellular signaling pathways in germinal center
  B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL)
year: '2015'
organisms: Homo sapiens
ndex: cc9efce9-dec0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4676894__12943_2015_474_Fig2_HTML.html
  '@type': Dataset
  description: 'Oncogenic (deregulated) intracellular signaling pathways in germinal
    center B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL). Germinal center
    B cell-like diffuse large B-cell lymphoma (GCB-DLBCL) are characterized by the
    inactivation or loss of the phosphatase and tensin homologue (PTEN) and S1PR2-Gα13-ARHGEF1
    signaling pathways, which both negatively modulate GC B cell migration and phosphatidylinositol-3-kinase
    (PI3K) signaling [, –, , ]. In addition, activating mutations of the histone methyltransferase
    EZH2 (enhancer of zeste homologue 2) and master regulator of the GCB phenotype
    promote epigenetic changes that, at least partly, cooperate with the B-cell lymphoma
    2 (BCL2) and BCL6 to mediate lymphomagenesis in GCB-DLBCL [, ]. A subset of GCB-DLBCL
    is characterized by translocations affecting the c-MYC and/or the BCL2 loci [,
    , ]. These translocations lead to constitutive activation of c-MYC and the anti-apoptotic
    BCL2 protein and to a malignant transformation by preventing terminal differentiation
    or blocking apoptosis. The different colors that are used in the figure indicate
    molecules that belong to a specific pathway and/or lead to a specific outcome.
    Adapted from REF: [, , , ]. Information for this figure was gleaned from the following
    references: [, , , –, , , , , –, , , , , , , –, , , , , –, –, , , , , –, –, ,
    ]. Abbreviations: S1PR2 sphingosine-1-phosphate receptor-2, Gα13 (GNA13) heterotrimeric
    G protein alpha 13, ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1, PI3K
    phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex
    1, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2, EZH2 enhancer
    of zeste homologue 2'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD58
  - PIK3CD
  - MYC
  - PIK3R3
  - KMT2B
  - TRB
  - EZH2
  - PIK3R6
  - P2RY8
  - TP53
  - TRG
  - RPTOR
  - BCL2
  - BCL6
  - CD2
  - PIK3CG
  - PTEN
  - AKT2
  - AKT1
  - AKT3
  - TRA
  - PIK3R5
  - PIK3CB
  - PIK3R4
  - MTOR
  - RHO
  - TRD
  - PIK3CA
  - S1PR2
  - Cancer
genes:
- word: CD58
  symbol: CD58
  source: hgnc_symbol
  hgnc_symbol: CD58
  entrez: '965'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: c-MYC
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MLL2
  symbol: MLL2
  source: hgnc_alias_symbol
  hgnc_symbol: KMT2B
  entrez: '9757'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: EZH2
  symbol: EZH2
  source: hgnc_symbol
  hgnc_symbol: EZH2
  entrez: '2146'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: P2RY8
  symbol: P2RY8
  source: hgnc_symbol
  hgnc_symbol: P2RY8
  entrez: '286530'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: PI3K/AKT/MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: BCL2
  symbol: BCL2
  source: hgnc_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: BCL6
  symbol: BCL6
  source: hgnc_symbol
  hgnc_symbol: BCL6
  entrez: '604'
- word: CD2
  symbol: CD2
  source: hgnc_symbol
  hgnc_symbol: CD2
  entrez: '914'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K/AKT/MTORC1signaling
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K/AKT/MTORC1signaling
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K/AKT/MTORC1signaling
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: +p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K/AKT/MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RHO
  symbol: RHO
  source: hgnc_symbol
  hgnc_symbol: RHO
  entrez: '6010'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: PI3K/AKT/MTORC1signaling
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: S1PR2
  symbol: S1PR2
  source: hgnc_symbol
  hgnc_symbol: S1PR2
  entrez: '9294'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
